Does the VA Cover Weight-Loss Drugs? (2026)

Short version: the Veterans Health Administration (VHA) does cover weight-loss drugs for enrolled veterans, but the path is narrower than for diabetes. GLP-1s used for type 2 diabetes (semaglutide, tirzepatide, dulaglutide) are handled through the VA National Formulary with facility-level criteria. The anti-obesity GLP-1s — Wegovy (semaglutide 2.4 mg), Zepbound (tirzepatide), and Saxenda (liraglutide 3.0 mg) — are non-formulary, meaning your VA prescriber must submit a non-formulary drug request documenting medical necessity.^[1][2] To qualify, you generally need a BMI of 30 or higher (or 27–29.9 with a weight-related condition), participation in the MOVE! weight-management program or another comprehensive lifestyle intervention, and a documented trial of cheaper formulary weight-loss agents first.^[3][4] When approved, the cost is dramatically lower than commercial — VA copays run from $0 to $33 per month, not $1,000+.^[5] Note: VA care for veterans is a separate system from Tricare, which covers active-duty members, retirees, and dependents — see our does Tricare cover weight-loss drugs guide for that side.

At a glance

• VA covers veterans, not the whole military. The Veterans Health Administration provides care to enrolled veterans through VA medical centers and the VA National Formulary. Active-duty service members, retirees, and dependents are covered by Tricare, a separate Department of Defense pharmacy benefit with different rules.^[6]
• Diabetes GLP-1s: generally available through the VA National Formulary with facility-level criteria. Semaglutide and tirzepatide for type 2 diabetes are the easier path.^[2][7]
• Weight-loss GLP-1s (Wegovy, Zepbound, Saxenda): non-formulary. Coverage requires a non-formulary drug request documenting medical necessity, reviewed by the local pharmacy/PBM team.^[1][3]
• Eligibility criteria: BMI ≥ 30 kg/m², OR BMI 27–29.9 with at least one weight-related condition (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, metabolic syndrome, osteoarthritis, MASLD), plus participation in the MOVE! program or another comprehensive lifestyle intervention.^[3][4]
• Step therapy: the VA generally expects a trial of cheaper formulary weight-loss medications first — phentermine/topiramate, orlistat, or naltrexone/bupropion are on the National Formulary with prior authorization; the injectable GLP-1s sit behind them.^[4]
• MOVE! is effectively a prerequisite. Pharmacotherapy is required to be paired with a comprehensive lifestyle intervention addressing diet, physical activity, and behavior — MOVE! is the VA's national program for this.^[3][8]
• Cost when covered: VA outpatient copays are tiered — Tier 3 brand drugs are $11/$22/$33 for a 30/60/90-day supply, with a $700 annual copay cap. Priority-group 1 veterans pay $0.^[5]
• VA pricing is structurally cheaper. The VA buys through the Federal Supply Schedule and national contracts, so the system's acquisition cost — and the veteran's copay — is far below commercial retail or cash price.^[9]

VA vs Tricare — make sure you're reading the right guide

This is the most common confusion, so it comes first. The Department of Veterans Affairs and the Department of Defense run two distinct health systems:

• VA / Veterans Health Administration — care and prescriptions for enrolled veterans, delivered at VA medical facilities (or community care) and dispensed under the VA National Formulary with VA copays. This article is about the VA.
• Tricare — the Department of Defense health plan for active-duty service members, retirees, National Guard/Reserve, and their family members. Tricare has its own formulary and prior-authorization rules and is administered through Express Scripts. If you are an active-duty member, a retiree, or a dependent, you want our does Tricare cover weight-loss drugs guide, not this one.^[6]

Some people qualify for both (for example, a military retiree who is also a service-connected veteran). If that's you, compare the copay and access rules in both systems — the VA's copays are often lower, but availability of the specific injectable can differ. For the broader payer landscape, see our GLP-1 coverage across Medicare, Medicaid, and commercial plans.

How the VA National Formulary treats GLP-1s

The VA does not have a commercial-style PBM formulary with copay tiers per drug in the way Express Scripts or CVS Caremark do. Instead it has the VA National Formulary plus drug-specific Criteria for Use (CFU) documents and Clinical Recommendations published by VA Pharmacy Benefits Management (PBM) Services.^[2] Three categories matter here:

• Formulary, no special criteria — routine agents a VA provider can prescribe directly.
• Formulary with Criteria for Use / prior authorization at the facility level — the drug is on the National Formulary, but the prescriber must document that the veteran meets published clinical criteria. The oral weight-loss agents (phentermine/topiramate, orlistat, naltrexone/bupropion) sit here.^[4]
• Non-formulary — the drug is not on the National Formulary; the prescriber must file a non-formulary drug request justifying why a formulary alternative won't work. Wegovy, Zepbound, and Saxenda for weight management fall in this bucket as of the August 2025 VA weight-management clinical recommendations.^[1][4]

The practical consequence: a diabetes GLP-1 is comparatively straightforward, while a weight-loss GLP-1 requires the extra non-formulary step. Per the VA's process, the non-formulary request is reviewed and a decision is required to be returned within 96 hours.^[3]

GLP-1 coverage for type 2 diabetes (the easier path)

For veterans with type 2 diabetes, the VA covers GLP-1 receptor agonists through the National Formulary with facility-level criteria. Semaglutide and tirzepatide are both listed in the VA Formulary Advisor for the diabetes indication, and a 2025 VA study following 201 veterans on semaglutide reported roughly 10% average body-weight loss alongside improvements in BMI, blood pressure, LDL cholesterol, triglycerides, and blood sugar over one year.^[7][10] The key point: when the drug is being used for diabetes, it is being managed against the diabetes criteria, not the weight-management non-formulary pathway — which is why so many veterans access semaglutide through their diabetes care.

For drug-level detail on the molecules involved, see our semaglutide drug page and tirzepatide drug page.

GLP-1 coverage for weight management (non-formulary, strict criteria)

This is where the VA gets restrictive. The three FDA-approved anti-obesity GLP-1s — Wegovy (semaglutide 2.4 mg, indicated for chronic weight management and, in a separate indication, cardiovascular risk reduction in adults with established CVD and overweight/obesity, per DailyMed SetID ee06186f-2aa3-4990-a760-757579d8f77b), Zepbound (tirzepatide, indicated for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity, per DailyMed SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b), and Saxenda (liraglutide 3.0 mg) — are non-formulary for the weight-management indication and require a non-formulary drug request.^[1][11]

Based on the VA's Wegovy weight-management Criteria for Use (revised August 2025) and the VA weight-management clinical recommendations, a veteran generally needs to meet all of the following before a non-formulary request will be approved:^[3][4]

1. BMI ≥ 30 kg/m², OR BMI 27–29.9 kg/m² with at least one weight-related condition — examples include hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, metabolic syndrome, osteoarthritis, or metabolic dysfunction–associated steatotic liver disease (MASLD).
2. Participation in a comprehensive lifestyle intervention (CLI) that targets all three pillars of weight management — diet, physical activity, and behavior. The VA's MOVE! program is the national vehicle for this and is effectively a prerequisite; enrollment is generally expected before pharmacotherapy is considered.
3. A documented trial of (or contraindication/intolerance to) lower-cost formulary weight-loss medications first — phentermine/topiramate, orlistat, or naltrexone/bupropion — before the injectable GLP-1 is approved.
4. Prescriber documentation of medical necessity explaining why a formulary alternative is inadequate, submitted as the formal non-formulary drug request.
5. Pregnancy safeguards. Before approval in a patient who can become pregnant, the provider confirms a negative pregnancy test and counsels on effective contraception.

Continuation / reauthorization follows the same logic as commercial anti-obesity policies: ongoing approval depends on documented clinical benefit (a meaningful percentage of weight loss) plus continued participation in the lifestyle program. Because the VA's exact reauthorization thresholds are set in the drug-specific CFU and can be revised, confirm the current renewal criteria with your VA pharmacy team rather than assuming a fixed number. For the weight-loss magnitudes that anchor these thresholds, compare options on our best semaglutide providers page.

MOVE! — the weight-management program prerequisite

MOVE! is the VA's national weight-management program. It is built around the same three pillars the CFU requires — nutrition, physical activity, and behavioral change — and is delivered through group classes, individual counseling, telehealth, and self-management tools at VA facilities.^[8] For weight-loss pharmacotherapy, MOVE! (or an equivalent comprehensive lifestyle intervention) is not optional garnish; it is the clinical context the VA requires the medication to sit inside. Practically:

• Enroll early. Because participation is part of the criteria, getting into MOVE! before (or at the same time as) requesting a GLP-1 removes a common reason for delay or denial.
• It documents the comorbidity and effort history your provider needs for the non-formulary request.
• It continues during treatment. Reauthorization generally requires ongoing program participation, not just an initial sign-up.

What it costs a veteran — VA copays vs commercial cash price

This is the VA's biggest advantage. The VA buys pharmaceuticals through the Federal Supply Schedule (FSS) and VA national contracts, which are negotiated against vendors' commercial pricing and frequently land below FSS for committed volume — so the system's acquisition cost is structurally lower than commercial retail.^[9] What the veteran actually pays is a tiered outpatient copay, not a percentage of an inflated list price:

• Tier 1 (preferred generics): $5 / $10 / $15 for a 30 / 60 / 90-day supply.^[5]
• Tier 2 (non-preferred generics): $8 / $16 / $24.^[5]
• Tier 3 (brand-name medicines — where Wegovy and Zepbound land): $11 / $22 / $33.^[5]
• Annual copay cap: once a veteran hits $700 in medication copays in a calendar year, additional prescriptions are free for the rest of the year.^[5]
• Priority-group 1 veterans pay $0 in medication copays (50%+ service-connected, individually unemployable, or Medal of Honor recipients); many other veterans qualify for copay exemptions based on disability rating or income.^[5]

How to actually get a weight-loss GLP-1 through the VA

A realistic step-by-step for an enrolled veteran:

1. Talk to your VA primary-care team and request a weight-management evaluation. Bring your weight history, prior diet/medication attempts, and any weight-related diagnoses (sleep apnea, hypertension, prediabetes, MASLD).
2. Enroll in MOVE! — or confirm you're in a comprehensive lifestyle intervention. This is a criterion, not a suggestion.^[8]
3. Ask for an obesity-medicine or endocrinology referral. These specialists prescribe GLP-1s most often and are most familiar with the non-formulary request process.
4. Try (or document intolerance to) the formulary oral agents if your provider thinks step therapy applies — phentermine/topiramate, orlistat, or naltrexone/bupropion.^[4]
5. Have your provider submit the non-formulary drug request for Wegovy, Zepbound, or Saxenda, documenting BMI, comorbidity, MOVE! participation, and prior trials. The local pharmacy/PBM team reviews it, with a decision due within 96 hours.^[3]
6. If your facility is short on injectable supply, ask about alternatives — a different agent, community care, or timing — rather than assuming denial.^[8]

If the VA denies or can't supply it — what works

Ranked by practicality:

• Appeal / resubmit the non-formulary request with stronger documentation. Many initial denials reflect missing criteria — no MOVE! enrollment, no documented prior-drug trial, or an unclear comorbidity. Tightening the documentation and resubmitting is often the highest-yield move.
• Use the diabetes pathway if it genuinely applies. If you have type 2 diabetes or prediabetes, the diabetes GLP-1 route is administered against different (easier) criteria.^[7]
• Check Tricare if you're dual-eligible. A military retiree who is also a service-connected veteran may have a Tricare path; the 2026 NDAA authorized Tricare to cover weight-loss drugs for obesity under a comprehensive treatment plan, though coverage was simultaneously narrowed for some Medicare-eligible retirees. See our Tricare weight-loss coverage guide.^[6]
• Cash-pay oral GLP-1s and self-pay vials. 2026 launches of the Wegovy pill and Lilly's oral Foundayo start near $149/month for the lowest dose; LillyDirect Self Pay vials run roughly $299–$699/month by dose. These are pricier than a VA copay but a fallback during supply gaps. Compounded semaglutide/tirzepatide via verified 503A telehealth is another lower-cost route, though it is not brand Wegovy/Zepbound and quality varies.
• Compare the broader payer landscape. For how commercial PBMs, Medicare, and Medicaid handle the same drugs, see our Medicare, Medicaid, and commercial coverage guide and our Express Scripts coverage review (Express Scripts also administers the Tricare pharmacy benefit).

Verdict — what most veterans should expect

For the median enrolled veteran asking does the VA cover weight-loss drugs: the answer is a qualified yes, gated by indication and process rather than a flat exclusion.

1. Diabetes GLP-1s (semaglutide, tirzepatide for type 2 diabetes): generally available through the VA National Formulary with facility-level criteria — the easiest path.^[7]
2. Weight-loss GLP-1s (Wegovy, Zepbound, Saxenda): non-formulary — covered only after a non-formulary drug request clears the BMI, comorbidity, MOVE!-participation, and prior-trial criteria.^[1][3]
3. MOVE! is the linchpin. Enrolling in the VA's weight-management program is effectively a prerequisite and supports both initial approval and reauthorization.^[8]
4. When covered, it's cheap. VA copays of $0–$33/month, capped at $700/year, make a covered fill the lowest-cost legitimate path available to veterans — far below commercial cash price.^[5][9]

The honest caveat is supply and approval friction, not cost: the cheapest route is also the one with the most paperwork and the most history of injectable shortages. Start the MOVE! enrollment and the obesity-medicine referral early, document everything, and treat the non-formulary request as a process to be cleared rather than a single yes-or-no question.

Further reading

• Does Tricare cover weight-loss drugs?
• GLP-1 coverage across Medicare, Medicaid, and commercial plans
• Does Express Scripts cover weight-loss drugs?